To the editor: I read with great interest the recent article by Cantillo et al. [1] . Interestingly, recent data suggest that tumor M2-pyruvate kinase may influence prognosis in a number of systemic malignancies besides colon carcinomas.
For instance, there is a close co-relationship between microvessel density as well as tumor prognosis in biliary tract carcinomas and biliary M2-pyruvate kinase levels. Using enzymelinked immunosorbent assay, biliary M2-pyruvate kinase has a sensitivity of nearly 90 % for identifying biliary tract carcinomas [2] . Similarly, tumor M2-pyruvate kinase plays a role in the evolution of gastric carcinomas. It does this by modulating p65 and Bcl-xL function [3] . Accentuated tumor expression by gastric carcinomas usually points to a poor clinical outcome and a worse prognosis. Higher tumor M2-pyruvate kinase levels are also seen in pancreatic malignancies and may help to distinguish aggressive exocrine tumor types from benign chronic pancreatitis [4] . The sensitivity of tumor M2-pyruvate kinase as a tumor marker in pancreatic malignancies is similar to CA 19.9 and averages to about 95 %.
Chemotherapeutic agents such as cyclosporine attenuate tumor M2-pyruvate kinase expression and thereby mitigate tumor growth in breast malignancies in a dose-dependent manner [5] . Tumor M2-pyruvate kinase can also be used in assessing prognosis in cervical carcinomas. For instance, the stage of the cervical malignancy correlates closely with tumor M2-pyruvate kinase levels [6] . A similar relationship between tumor prognosis and tumor M2-pyruvate kinase levels is seen in pulmonary malignancies. In fact, use of agents such as cisplatin in conjunction with tumor M2-pyruvate kinase interfering RNA results in enhanced apoptosis and attenuates tumor growth in pulmonary malignancies [7] . The tumor volume is markedly reduced following administration of the combination.
The above examples clearly illustrate the evolving role of tumor M2-pyruvate kinase in oncology and the need for further studies to fully elaborate its prognostic role in other gastrointestinal malignancies.
